Innate Pharma and Sanofi collaborate on new ADCs

France-based Innate Pharma (Euronext Paris: IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases, has entered into a collaboration agreement with French pharma major Sanofi (Euronext: SAN) to apply its site-specific conjugation technology to the development of new antibody drug conjugates (ADC). Innate Pharma’s shares rose 2.8% to 9.05 euros on the news on Friday.

Hervé Brailly, chief executive and co-founder of Innate Pharma, said: "We are very pleased to collaborate with Sanofi, a global health care leader. By combining some of Sanofi R&D's anti-tumor antibodies with our novel technology for conjugating cytotoxic compounds, this collaboration opens the gate to next-generation ADCs with a potentially improved therapeutic index for patients with cancer."

Option for licensing agreement